Back

Global Learning Collaborative

  • Antipsychotic Agents
  • Tardive Dyskinesia

Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 0.25 creditsAMA PRA Category 1 Credit™Up to 0.25 creditsNursingUp to 0.25 creditsPharmacyUp to 0.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Board review / self-assessment
  • includes Recorded-from-live session
  • Credit · Up to 0.25 credits
  • Commercial Support
  • Released
    Oct 30, 2025
  • Last day to claim credit
    Oct 31, 2026 3 weeks left